| Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures R Vander Velde, N Yoon, V Marusyk, A Durmaz, A Dhawan, ... Nature communications 11 (1), 2393, 2020 | 101 | 2020 |
| Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations D Miroshnychenko, E Baratchart, MC Ferrall-Fairbanks, RV Velde, ... Nature Ecology & Evolution 5 (3), 379-391, 2021 | 67 | 2021 |
| Novel role of pleckstrin homology domain of the Bcr-Abl protein: Analysis of protein–protein and protein–lipid interactions D Miroshnychenko, A Dubrovska, S Maliuta, G Telegeev, P Aspenström Experimental cell research 316 (4), 530-542, 2010 | 42 | 2010 |
| Development of Bioselective Element of SPR Spectrometer for Monitoring of Oligonucleotide Interactions and Comparison with Thermodynamic Calculations A Rachkov, Y Holodova, Y Ushenin, D Miroshnichenko, G Telegeev, ... Sensor Letters, 7 (5), pp. 957-961(5), 2009 | 17 | 2009 |
| Stroma-mediated breast cancer cell proliferation indirectly drives chemoresistance by accelerating tumor recovery between chemotherapy cycles D Miroshnychenko, T Miti, P Kumar, A Miller, M Laurie, N Giraldo, MM Bui, ... Cancer research 83 (22), 3681-3692, 2023 | 6 | 2023 |
| The impact of tumor stromal architecture on therapy response and clinical progression PM Altrock, N Yoon, JA Bull, H Wu, J Ruiz-Ramírez, D Miroshnychenko, ... bioRxiv, 451047, 2018 | 6 | 2018 |
| Analysis of GEF activity of Bcr protein DH domain DO Miroshnychenko, HD Teleheiev, SS Maliuta Ukrains' kyi Biokhimichnyi Zhurnal (1999) 79 (5), 116-121, 2007 | 6 | 2007 |
| Protein-lipid and protein-protein interactions of Bcr PH domain DO Miroshnychenko, AM Dubrovska, GD Telegeev, SS Maliuta Biopolymers & Cell 23 (5), 405, 2007 | 3 | 2007 |
| Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators B Desai, T Miti, S Prabhakaran, D Miroshnychenko, M Henry, V Marusyk, ... bioRxiv, 2024.04. 24.590626, 2024 | 1 | 2024 |
| Paracrine enhancement of tumor cell proliferation provides indirect stroma-mediated chemoresistance via acceleration of tumor recovery between chemotherapy cycles D Miroshnychenko, T Miti, A Miller, P Kumar, M Laurie, MM Bui, ... bioRxiv, 2023.02. 07.527543, 2023 | 1 | 2023 |
| Abstract B008: Therapy-protective peristromal niches mediate positive ecological interaction between therapy-sensitive and therapy-resistant cells, altering the evolutionary … M Robertson-Tessi, B Desai, T Miti, P Kumar, S Yarlagadda, R Shah, ... Cancer Research 84 (22_Supplement), B008-B008, 2024 | | 2024 |
| Abstract C035: Spatially limited stroma-mediated resistance potentiates targeted therapy resistance through an integration of multiple juxtacrine and paracrine mechanisms B Desai, T Miti, S Prabhakaran, D Miroshnychenko, M Henry, V Marusyk, ... Cancer Research 84 (22_Supplement), C035-C035, 2024 | | 2024 |
| Abstract A040: A novel stroma-mediated positive interaction between resistant and sensitive cells in non-small cell lung cancer facilitates drug resistance RM Shah, S Yarlagadda, M Robertson-Tessi, B Desai, T Miti, ... Cancer Research 84 (22_Supplement), A040-A040, 2024 | | 2024 |
| Dissecting the Spatially Restricted Effects of Microenvironment-Mediated Resistance on Targeted Therapy Responses T Miti, B Desai, D Miroshnychenko, D Basanta, A Marusyk Cancers 16 (13), 2405, 2024 | | 2024 |
| Positive ecological interaction between therapy-resistant and sensitive cells, mediated by stromal niche, slows the expansion of resistant subpopulations and promotes tumor … B Desai, M Robertson-Tessi, R Vander Velde, T Miti, S Yarlagadda, ... CANCER RESEARCH 84 (3), 2024 | | 2024 |
| Abstract A016: Positive ecological interaction between therapy-resistant and sensitive cells, mediated by stromal niche, slows the expansion of resistant subpopulations and … B Desai, M Robertson-Tessi, RV Velde, T Miti, S Yarlagadda, R Shah, ... Cancer Research 84 (3_Supplement_2), A016-A016, 2024 | | 2024 |
| Abstract B023: Paracrine enhancement of tumor cell proliferation provides indirect stroma-mediated chemoresistance via acceleration of tumor recovery between chemotherapy cycles D Miroshnychenko, T Miti, P Kumar, A Miller, M Laurie, N Giraldo, MM Bui, ... Cancer Research 84 (3_Supplement_2), B023-B023, 2024 | | 2024 |
| Abstract A024: Ploidy as a predictive biomarker for gemcitabine sensitivity in triple-negative breast cancers V Tagal, J Cole, D Miroshnychenko, A Marusyk, N Andor Cancer Research 84 (3_Supplement_2), A024-A024, 2024 | | 2024 |
| Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling Q Hu, LLR Rix, B Desai, D Miroshnychenko, X Li, EA Welsh, B Fang, ... bioRxiv, 2024.08. 27.609975, 2024 | | 2024 |
| Abstract B084: Sotorasib/SHP2 inhibitors combo, KRASG12C (ON) I and RASMULTI (ON) I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C … HS Solanki, D Imbody, B Desai, R Kato, PA Stewart, Y Stern, A Majumder, ... Molecular Cancer Therapeutics 22 (12_Supplement), B084-B084, 2023 | | 2023 |